Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Blockade in Preventing Postoperative Atrial Fibrillation
NCT03269383Phase 4Withdrawn
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Postoperative Atrial Fibrillation at 7 days. Planned start Dec 2019; status: withdrawn.
02
Drugs
bupivacaine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03269383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269383.